Ypsomed and i-SENS global partnership signing ceremony
Simon Michel , CEO Ypsomed and Geun Sig Cha, CEO i-SENS

Ypsomed enters new partnerships in diabetes therapy

Press Releases Ypsomed Group

Burgdorf – By entering into new partnerships and cooperations, Ypsomed has expanded its diabetes therapy offerings. With the goal of freedom of choice for the users of the mylife YpsoPump, the first study on the insulin pump with open interfaces as well as the connection to the therapy management solution diasend® by Glooko starts. In addition, Ypsomed launches the new blood glucose monitoring system mylife Aveo in spring 2020.

Lees meer...

Ypsomed expands headquarters in Burgdorf

Ypsomed expands headquarters in Burgdorf

Press Releases Ypsomed Group

Burgdorf – Ypsomed opens its new and renovated buildings at the headquarters in Burgdorf. With this expansion, Ypsomed secures the additional capacities and workplaces it needs to continue growing in the future.

Lees meer...

Ypsomed opens production plant in Schwerin, Germany

Ypsomed opens production plant in Schwerin

Press Releases Ypsomed Group

Burgdorf – Ypsomed opens its new production plant in Schwerin, in north-eastern Germany. Ypsomed is thus ensuring the necessary production capacities for growth in the coming years. Around 200 jobs will be created at the new production site over the next few years.

Lees meer...

Ypsomed expands to North America

Ypsomed increases EBIT and invests in long-term profitability

Press Releases Ypsomed Group

Burgdorf – In the financial year 2018/19, Ypsomed achieved consolidated sales of CHF 453.8 million (previous year: CHF 466.1 million). In continuing operations, Ypsomed achieved a sales growth of CHF 68.4 million, which represents an increase of 24%. The operating result (EBIT) amounts to CHF 73.3 million (previous year: CHF 61.1 million). Net profit for the 2018/19 financial year amounts to CHF 60.1 million (previous year: CHF 52.1 million).

Lees meer...

Copaxone PEN from Teva
Copaxone PEN

Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the second commercial market entry of Ypsomed’s autoinjector YpsoMate®.

Lees meer...